Related Experiment Video

Updated: Mar 6, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K

Enterovirus D68-Associated Community-Acquired Pneumonia in the Pediatric Age Group

Samantha Bosis1, Susanna Esposito2,3

  • 1Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.

Current Infectious Disease Reports
|March 3, 2017
PubMed

Insights

Enterovirus D68 (EV-D68) is an emergent pathogen causing severe pneumonia in children. Increased global surveillance and rapid diagnostics are crucial for managing EV-D68 outbreaks.

Area of Science:

  • Pediatric infectious diseases
  • Virology
  • Respiratory medicine

Background:

  • Enterovirus D68 (EV-D68) is a viral pathogen first identified in 1962.
  • Historically, EV-D68 was rarely detected in respiratory samples.
  • Recent outbreaks have highlighted EV-D68 as a significant cause of pediatric respiratory illness.

Purpose of the Study:

  • To review current knowledge on Enterovirus D68 (EV-D68) in pediatric community-acquired pneumonia (CAP).
  • To summarize the role of EV-D68 in severe respiratory illnesses in children.

Main Methods:

  • Literature review of existing studies and reports on EV-D68.
  • Analysis of epidemiological data and clinical presentations associated with EV-D68 infections.

Main Results:

  • EV-D68 has emerged as a cause of severe, life-threatening respiratory diseases, including pneumonia, in children.
  • Outbreaks in 2014 and subsequent reports indicate a global rise in EV-D68-associated illnesses.
  • Children with underlying conditions like prematurity or chronic diseases are particularly vulnerable.

Conclusions:

  • There are no specific treatments or vaccines for EV-D68 infections.
  • Enhanced global surveillance is essential for early detection and response.
  • Development and implementation of sensitive, rapid diagnostic methods are critical for managing EV-D68 outbreaks.
Abstract

Keywords:
ChildrenCommunity-acquired pneumoniaEV-D68Enterovirus D68Respiratory distressRespiratory tract infections

More Related Videos

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

12.6K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.4K

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.8K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.1K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
3.7K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
976
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.1K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.3K